BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34426799)

  • 1. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity.
    Nguyen H; Salkeld J; Agarwal S; Goodman A
    Clin Infect Pract; 2021 Nov; 12():100089. PubMed ID: 34426799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
    Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
    J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
    Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
    J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
    Kurshan A; Snell LB; Prior L; Tam JCH; Graham C; Thangarajah R; Edgeworth JD; Nebbia G; Doores KJ
    Oxf Open Immunol; 2023; 4(1):iqac012. PubMed ID: 36844257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
    Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
    Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
    Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
    Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan.
    Katsuo C; Kubota K; Tanaka K; Kurita Y; Nakajima A
    Intern Med; 2023; 62(12):1765-1770. PubMed ID: 37316279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effectiveness of REGN-COV2 in Patients with COVID-19 in Japan: A Retrospective Cohort Study with a Bayesian Inference.
    Amano N; Iwata K; Iwata S
    Infect Chemother; 2021 Dec; 53(4):767-775. PubMed ID: 34979607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.
    Soresina A; Moratto D; Chiarini M; Paolillo C; Baresi G; Focà E; Bezzi M; Baronio B; Giacomelli M; Badolato R
    Pediatr Allergy Immunol; 2020 Jul; 31(5):565-569. PubMed ID: 32319118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia.
    Almontasheri A; Al-Husayni F; Alsuraihi AK; Binyahib H; Albanna AS
    Am J Case Rep; 2021 Feb; 22():e929447. PubMed ID: 33612712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
    Luitel P; Vais D; Gidron A
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab335. PubMed ID: 34405092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia.
    Rise N; Touborg T; Lundsted DH; Dalager-Pedersen M; Mogensen TH
    Front Immunol; 2022; 13():1057065. PubMed ID: 36505407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
    Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
    bioRxiv; 2020 Dec; ():. PubMed ID: 33299993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature.
    Devassikutty FM; Jain A; Edavazhippurath A; Joseph MC; Peedikayil MMT; Scaria V; Sandhya P; Govindaraj GM
    Pediatr Allergy Immunol Pulmonol; 2021 Sep; 34(3):115-118. PubMed ID: 34495748
    [No Abstract]   [Full Text] [Related]  

  • 18. T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review.
    Chawla S; Jindal AK; Arora K; Tyagi R; Dhaliwal M; Rawat A
    Clin Rev Allergy Immunol; 2023 Aug; 65(1):31-42. PubMed ID: 35708830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
    Hegazy AN; Krönke J; Angermair S; Schwartz S; Weidinger C; Keller U; Treskatsch S; Siegmund B; Schneider T
    BMC Infect Dis; 2022 Jun; 22(1):537. PubMed ID: 35692034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.